Herbal Monograph
Bacopa
Bacopa monnieri (L.) Wettst.
Plantaginaceae (formerly Scrophulariaceae)
Ayurveda's premier brain tonic — modern neuroscience validates centuries of traditional use for memory and cognitive enhancement.
Overview
Plant Description
Small, creeping, succulent perennial herb, 10-30 cm tall, forming dense mats in wet habitats. Stems prostrate, rooting at the nodes, glabrous, fleshy, and branching. Leaves opposite, sessile, oblong-obovate to spatulate, 8-25 mm long, 3-8 mm wide, entire margins, fleshy and succulent, dotted with minute glands, with obscure pinnate venation. Flowers small, solitary, axillary, on slender pedicels 6-30 mm long. Corolla white, pale blue, or light purple, 5-lobed, 8-10 mm across, bell-shaped with a yellow center. Sepals 5, unequal. Stamens 4, didynamous. Fruit a small ovoid capsule, 4-5 mm long, enclosed by persistent sepals, containing numerous minute seeds. The entire plant has a slightly bitter taste when fresh. Propagation is primarily vegetative via stem cuttings that root readily at nodes, though seed propagation is also viable.
Habitat
Wetlands, marshes, and waterlogged areas throughout tropical and subtropical regions. Thrives in shallow freshwater margins, muddy banks of ponds, lakes, rivers, and rice paddies. Tolerates slightly brackish water. Grows in full sun to partial shade, requiring consistently moist to waterlogged soils. Altitude range from sea level to approximately 1400 m. Prefers warm, humid conditions with temperatures of 20-35 degrees C. Can grow as an aquatic, semi-aquatic, or terrestrial plant in wet soil. Often found in disturbed wet habitats and is somewhat weedy in suitable conditions.
Distribution
Native to the Indian subcontinent (India, Pakistan, Sri Lanka, Nepal, Bangladesh). Now found throughout tropical and subtropical regions worldwide, including Southeast Asia, southern China, Taiwan, Australia, Africa, Madagascar, the southern United States (Florida, Texas, Louisiana, Hawaii), Central America, and South America. In the United States, naturalized in the southeastern states and considered native to some coastal wetland habitats. India remains the primary source for medicinal harvest and commercial cultivation, particularly the states of Kerala, Tamil Nadu, Karnataka, and West Bengal.
Parts Used
Whole plant (aerial parts — leaves and stems)
Preferred: Standardized extract (capsule or tablet), dried whole herb powder, fresh juice (traditional)
The whole aerial portion is used in traditional Ayurvedic practice and in most commercial preparations. The succulent leaves are considered the primary reservoir of bacosides. In traditional practice, the fresh juice of the whole plant (swarasa) is described in classical texts. Modern standardized extracts (CDRI 08/KeenMind, BacoMind, Synapsa) use the whole dried aerial parts as starting material. The root is not typically used medicinally.
Fresh juice (swarasa)
Preferred: Fresh-pressed juice of whole plant, mixed with ghee or honey
The traditional Ayurvedic preparation method. Fresh whole plant is crushed and the juice extracted. Described in the Charaka Samhita as the preferred form for medhya rasayana (brain tonic) applications. Dose of fresh juice is typically 10-20 mL, often mixed with ghee or honey as an anupana (vehicle). Difficult to standardize and not commercially practical for the supplement market, but remains the form described in classical texts.
Key Constituents
Bacosides (triterpenoid saponins — primary active compounds)
Bacosides are dammarane-type triterpenoid saponins and are the principal pharmacologically active constituents of Bacopa monnieri. They are responsible for the cognitive-enhancing, anxiolytic, and neuroprotective effects observed in both animal and human studies. Mechanisms include: (1) antioxidant protection of neurons from lipid peroxidation and free radical damage, particularly in the hippocampus and frontal cortex; (2) enhancement of acetylcholinesterase activity and modulation of cholinergic neurotransmission; (3) upregulation of serotonin (5-HT) and dopamine levels; (4) promotion of dendritic branching and synaptic activity in hippocampal neurons; (5) modulation of stress-related GABA, 5-HT, and dopamine receptor pathways. Standardization to total bacoside content (typically 20-55% depending on extract type) is essential for clinical reproducibility.
Bacosaponins and related glycosides
The bacosaponins and bacopasides collectively form the saponin complex responsible for Bacopa's therapeutic effects. The structural diversity of the saponin fraction (different aglycones, sugar chains, and acylation patterns) contributes to the herb's multi-target pharmacology. Standardization of commercial extracts captures this complex rather than isolated single compounds, which is thought to be important for clinical efficacy.
Alkaloids
Alkaloids are minor constituents of Bacopa monnieri. While early research focused on brahmine and herpestine, modern investigations have established that the triterpenoid saponins (bacosides) rather than the alkaloids are the primary bioactive compounds responsible for cognitive and anxiolytic effects. The alkaloids may contribute marginally to the overall pharmacological profile but are not the basis for standardization or clinical dosing.
Flavonoids and phytosterols
Flavonoids and phytosterols are secondary constituents that may contribute to Bacopa's antioxidant, anti-inflammatory, and anxiolytic activity through complementary mechanisms. Apigenin's GABAergic anxiolytic activity is well-documented in its own right and may synergize with the bacoside-mediated anxiolytic effects. These compounds provide a supporting pharmacological role rather than the primary therapeutic activity.
Other constituents
Minor constituents providing additional phytochemical complexity. D-mannitol is not therapeutically relevant. Hersaponin's sedative activity was noted in early pharmacological research but is not considered a major contributor to Bacopa's clinical effects at standard doses.
Herbal Actions
Enhances cognitive function, memory, and mental performance
The most well-established and clinically validated action of Bacopa monnieri. Nootropic activity encompasses enhancement of memory acquisition, memory consolidation, and memory retention. Multiple RCTs have demonstrated significant improvements in cognitive domains including working memory, attention, cognitive processing speed, and verbal learning in both healthy adults and elderly populations. The effect requires sustained administration (typically 8-12 weeks) rather than acute dosing; Bacopa is not a stimulant and does not produce immediate cognitive effects. Mechanism involves bacoside-mediated enhancement of hippocampal synaptic activity, promotion of dendritic branching, modulation of acetylcholine, serotonin, and dopamine neurotransmitter systems, and antioxidant protection of neural tissue. Stough et al. 2001 and 2008 demonstrated significant improvements in speed of information processing, working memory, and learning rate after 90 days of CDRI 08 (300 mg/day). Roodenrys et al. 2002 found significant effects on retention of new information.
[5, 6, 7, 8, 9]Supports and calms the nervous system
Bacopa acts as a nervine tonic (nerve-nourishing agent) that supports and strengthens nervous system function over time. Distinguished from stimulant nervines (like caffeine) and sedative nervines (like valerian) in that Bacopa primarily restores and sustains neural function rather than acutely exciting or sedating. Traditional Ayurvedic classification as a medhya rasayana (intellect-promoting rejuvenative) aligns with the modern understanding of nervine tonic activity. Promotes neuronal repair, enhances nerve impulse transmission, and supports neurotransmitter balance. Animal studies demonstrate increased dendritic length and branching in hippocampal and basolateral amygdala neurons after chronic Bacopa administration.
[6, 14]Reduces anxiety
Bacopa demonstrates clinically significant anxiolytic (anti-anxiety) effects in human trials. Stough et al. 2001 found reduced State Anxiety scores after 90 days of Bacopa (CDRI 08, 300 mg/day). Calabrese et al. 2008 systematic review noted anxiolytic effects across multiple studies. The anxiolytic effect appears to be mediated through modulation of GABAergic, serotonergic, and dopaminergic neurotransmission rather than through direct sedation. Animal studies show that bacosides modulate 5-HT2C and 5-HT1A receptor activity and enhance GABA levels in the brain. Unlike benzodiazepines, Bacopa does not appear to impair cognitive function; rather, the anxiolytic and nootropic effects occur simultaneously. This dual action makes it particularly suitable for anxiety accompanied by cognitive difficulty or 'brain fog.'
[6, 7, 14]Prevents or slows oxidative damage to cells
Bacosides and associated flavonoids (apigenin, luteolin) provide significant antioxidant activity, particularly relevant to neuroprotection. Bacopa constituents scavenge superoxide anion, hydroxyl radical, and nitric oxide radicals. They inhibit lipid peroxidation in brain tissue homogenates. Upregulation of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) has been demonstrated in animal models. This antioxidant activity is considered a key mechanism underlying neuroprotection against age-related cognitive decline and neurodegenerative processes.
[6, 14]Reduces inflammation
Bacopa demonstrates anti-inflammatory activity through inhibition of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta), modulation of NF-kB signaling, and inhibition of COX-2 and 5-LOX pathways. Animal studies show reduced neuroinflammation in models of Alzheimer's disease and other neurodegenerative conditions. Peripheral anti-inflammatory effects have also been documented. The anti-inflammatory action supports the neuroprotective profile by reducing chronic neuroinflammation associated with cognitive decline.
[14]Helps the body adapt to stress and restore homeostasis
Bacopa demonstrates adaptogenic properties, helping to normalize physiological responses to stress. Animal studies show that chronic Bacopa administration attenuates stress-induced elevations in cortisol, reduces stress-related ulcers, and normalizes catecholamine levels and adrenal gland weight under chronic stress conditions. In human trials, reductions in anxiety and cortisol levels support an adaptogenic mechanism. Bacopa modulates the HPA (hypothalamic-pituitary-adrenal) axis and Hsp70 (heat shock protein) expression under stress. While not as commonly classified as an adaptogen compared to ashwagandha or rhodiola, the evidence supports this categorization.
[6, 14]Modulates and balances immune function
Bacopa demonstrates immunomodulatory activity in animal and in vitro studies. Enhances both humoral and cell-mediated immune responses. Increases macrophage phagocytic activity, promotes lymphocyte proliferation, and modulates cytokine production. Beta-sitosterol and other phytosterols may contribute to this action. Clinical significance of immunomodulatory effects at standard nootropic doses is not well-established in human trials.
[14]Therapeutic Indications
Nervous System
Memory enhancement and cognitive function in healthy adults
The most studied indication for Bacopa monnieri. Kongkeaw et al. 2014 meta-analysis of 9 RCTs (n=518) concluded that Bacopa significantly improved attention, cognitive processing, and working memory. Stough et al. 2001 RCT (n=46): CDRI 08 extract (300 mg/day for 90 days) significantly improved speed of visual information processing, learning rate, and memory consolidation (P<0.05). Stough et al. 2008 follow-up study confirmed chronic effects on working memory with improved performance on Stroop task (P<0.05). Roodenrys et al. 2002 RCT (n=76): 300 mg/day for 12 weeks significantly improved acquisition and retention of verbal learning (P<0.05). Pase et al. 2012 RCT (n=62): CDRI 08 (300 mg/day, 90 days) improved spatial working memory accuracy and reduced choice reaction time latency. KEY POINT: Effects require chronic administration (8-12 weeks minimum); no acute cognitive enhancement has been reliably demonstrated. Standard dose: 300-450 mg standardized extract daily.
[5, 7, 8, 9, 10]Age-related cognitive decline and neuroprotection
Raghav et al. 2006 RCT in elderly participants (>65 years): 12 weeks of Bacopa (300 mg/day) improved attention, verbal learning, and delayed recall compared to placebo. Calabrese et al. 2008 systematic review concluded that Bacopa shows promise for age-related cognitive decline through multiple neuroprotective mechanisms. Animal models of Alzheimer's disease demonstrate that bacosides reduce beta-amyloid aggregation, decrease acetylcholinesterase activity, increase acetylcholine levels, and attenuate oxidative damage and neuroinflammation in the hippocampus. These neuroprotective effects provide a plausible basis for potential disease-modifying activity, though human evidence is limited to cognitive outcomes in mild decline rather than diagnosed dementia.
[6, 11, 14]Anxiety and stress
Multiple human trials have demonstrated significant anxiolytic effects. Stough et al. 2001: significant reduction in State Anxiety scores (STAI) after 90 days. Benson et al. 2014 RCT (n=17, crossover design): single and multi-dose CDRI 08 improved mood and reduced cortisol levels during a multi-tasking cognitive stress paradigm. Calabrese et al. 2008 review noted consistent anxiolytic findings across studies. The anxiolytic mechanism involves modulation of serotonergic (5-HT1A agonism, 5-HT2C modulation) and GABAergic systems. Animal studies confirm dose-dependent anxiolytic effects comparable to lorazepam in elevated plus-maze and open-field tests, without the motor impairment or cognitive blunting associated with benzodiazepines.
[6, 7, 14]ADHD (adjunctive therapy in children and adults)
Dave et al. 2014 open-label study in children (n=31, ages 6-12) with ADHD: Bacopa (standardized extract, 225 mg/day for 6 months) showed improvements in restlessness, self-control, attention, and learning problems on the Conners' Parent Rating Scale. Kean et al. 2016 RCT (n=36 children): CDRI 08 extract showed improvements in sentence repetition, logical memory, and paired associate learning. Negi et al. 2000 open-label trial in children (n=40) reported improvements in comprehension, memory, and perception. While promising, the evidence base for ADHD is limited by small sample sizes, predominantly open-label designs, and lack of comparison with standard ADHD treatments. Larger well-designed RCTs are needed before Bacopa can be recommended as a standard adjunctive treatment for ADHD.
[6, 14]Epilepsy (traditional adjunctive use)
One of the classical Ayurvedic indications for Brahmi. Charaka Samhita and Sushruta Samhita describe Bacopa for apasmara (epilepsy). Animal models support anticonvulsant activity: bacosides raise seizure threshold and reduce seizure severity in pentylenetetrazol-induced and pilocarpine-induced seizure models. Anticonvulsant mechanism may involve GABAergic modulation. However, no controlled human clinical trials have been conducted for epilepsy. This remains a traditional indication supported by preclinical evidence only. NOT a substitute for anticonvulsant medications.
[14]Immune System
Immunomodulation and immune support
Animal and in vitro studies demonstrate that Bacopa extracts enhance both humoral and cell-mediated immune responses. Increased macrophage phagocytic activity, augmented lymphocyte proliferation, and enhanced antibody production have been documented. Immunomodulatory effects are attributed to bacosides, phytosterols, and flavonoids. Clinical evidence in humans for immune-specific outcomes is lacking. The adaptogenic stress-modulating effects may indirectly support immune function by attenuating stress-induced immunosuppression.
[14]Digestive System
Irritable bowel syndrome and intestinal spasms (traditional use)
Traditional Ayurvedic use for digestive complaints including intestinal spasms and irregularity. Bacopa demonstrates antispasmodic activity on smooth muscle in animal studies, mediated through calcium channel antagonism. Some Ayurvedic formulations include Bacopa for its bitter tonic and carminative properties. Modern clinical evidence for GI-specific indications is absent. The bitter taste stimulates digestive secretions (classic bitter tonic mechanism). Interestingly, the most common side effects of Bacopa supplementation are GI-related (nausea, cramping), which suggests significant bioactivity in the GI tract.
[14]Cardiovascular System
Cardiovascular protection and antioxidant support
Animal studies demonstrate that Bacopa extracts protect cardiac tissue from oxidative stress, reduce lipid peroxidation in cardiac tissue, and have mild vasodilatory effects mediated through endothelium-dependent nitric oxide release. Bacopa may also have mild antihypertensive effects through its adaptogenic stress-reducing mechanisms and direct vascular relaxation. Hersaponin, a minor saponin constituent, demonstrated cardiotonic activity in early pharmacological studies. Clinical evidence for cardiovascular-specific outcomes in humans is very limited. Cardiovascular benefits are secondary to the primary nootropic and neuroprotective actions.
[14]Energetics
Temperature
cool
Moisture
moist
Taste
Tissue States
hot/excitation, dry/atrophy
In Ayurvedic energetics, Bacopa (Brahmi) has a bitter and astringent taste (rasa), a cooling energy (virya), and a sweet post-digestive effect (vipaka). It pacifies all three doshas but is most specific for pitta and vata imbalances. Its cooling nature makes it suitable for pitta-type neurological conditions (irritability, inflammation-driven cognitive issues) while its nervine tonic and rejuvenative properties address vata-type depletion (anxiety, nervousness, mental exhaustion). It slightly increases kapha in excess due to its heavy, moist qualities but is generally tridoshic. In Western energetic terms, Bacopa is considered cooling and moistening, appropriate for hot and dry tissue states associated with nervous system depletion, burnout, and anxiety with irritability. This cooling energetic profile distinguishes it from warming nootropic herbs like rosemary or gotu kola (which is closer to neutral). Bacopa is particularly well-suited for individuals with nervous system depletion accompanied by heat signs (inflammation, irritability, restlessness).
Traditional Uses
Ayurveda
- Medhya rasayana (brain tonic / intellect-promoting rejuvenative): One of the four principal medhya rasayanas described in the Charaka Samhita alongside Shankhapushpi (Convolvulus pluricaulis), Yashtimadhu (Glycyrrhiza glabra), and Mandookaparni (Centella asiatica)
- Enhancement of memory (smriti), intellect (dhi), and comprehension (dhriti)
- Treatment of apasmara (epilepsy and seizure disorders)
- Unmada (insanity/psychosis) — used in classical formulations for mental health conditions
- Nervine tonic for children — given to promote learning, speech development, and cognitive ability from young age
- Rasayana (rejuvenative) for the nervous system — promotes longevity and prevents nervous system aging
- Anxiety, restlessness, and disturbed sleep associated with mental overexertion
- Voice improvement and promotion of clear speech (swarasa used for saraswati — eloquence)
- External paste applied to joints for anti-inflammatory effects
"Bacopa monnieri is described in the Charaka Samhita (c. 6th century CE) as one of the premier medhya rasayana herbs -- substances that enhance intellect, memory, and cognitive function while providing rejuvenative benefits to the nervous system. The name 'Brahmi' derives from Brahma, the Hindu deity of creation and knowledge, reflecting the plant's exalted status as a promoter of supreme consciousness. The Charaka Samhita (Chikitsasthana, Chapter 1) specifically describes the fresh juice of Brahmi taken with ghee or milk as a medhya rasayana. Sushruta Samhita also references Brahmi for memory and epilepsy. The plant appears in the Atharva Veda (c. 800 BCE) where it is described as a 'brain food' that sharpens intellect and mental acuity. In the traditional Ayurvedic classification, Brahmi is bitter and astringent in taste (rasa), cooling in potency (virya), and sweet in post-digestive effect (vipaka). It pacifies pitta and vata doshas."
Traditional Indian folk medicine
- Memory tonic for students and scholars
- Treatment of epilepsy and convulsions in children
- Remedy for asthma and bronchitis (expectorant use)
- Treatment of snake bites (external application)
- Diuretic in dropsy (edema)
- Anti-inflammatory poultice for swollen joints
- General tonic for debility and convalescence
- Treatment of skin diseases and ulcers (topical application)
"Beyond classical Ayurvedic texts, Bacopa has deep roots in folk medicine traditions across the Indian subcontinent. Rural practitioners (vaidyas) have used Brahmi for centuries as a children's tonic to promote intellectual development and speech. In Kerala and South Indian traditions, Brahmi is given to children as a brain tonic from early childhood, often as fresh juice with honey. Folk medicinal uses extend beyond cognitive applications to include asthma, skin diseases, and as a general tonic. The plant's association with water (it grows in wetlands) is symbolically linked to its cooling, calming properties in folk understanding."
[14]
Southeast Asian traditional medicine
- Memory enhancement and cognitive support
- Treatment of epilepsy
- Remedy for fever and inflammation
- Treatment of ulcers and wounds (topical)
- Used as a vegetable and pot herb in some regions
"Bacopa monnieri is found wild throughout Southeast Asia and is used in traditional medicine systems of Thailand, Vietnam, and other countries in the region. Uses largely parallel the Indian Ayurvedic tradition with emphasis on cognitive enhancement and nervous system support. In some regions, the fresh plant is consumed as a vegetable or salad green."
[14]
Modern Research
Meta-analysis of Bacopa for cognitive function
Meta-analysis of 9 randomized, double-blind, placebo-controlled trials (total n=518) evaluating Bacopa monnieri extract for cognitive enhancement in healthy adults and elderly subjects.
Findings: Bacopa significantly improved attention (P=0.001), cognitive processing speed (P=0.003), and working memory (P=0.01) compared to placebo. The effect was consistent across multiple cognitive domains. Studies using standardized extracts (primarily CDRI 08 at 300 mg/day) for durations of 12 weeks or longer showed the most robust effects. The meta-analysis confirmed that chronic administration is required for measurable cognitive benefits.
Limitations: Heterogeneity in cognitive outcome measures across studies. Variable Bacopa extracts used (though CDRI 08 predominated). Most studies were of short-to-moderate duration (12-16 weeks). Limited data on long-term cognitive effects beyond 6 months. Studies predominantly conducted in Australian and Indian populations.
[5]
Systematic review of Bacopa for cognitive enhancement
Systematic review of the human clinical trial evidence for Bacopa monnieri as a cognitive enhancer, examining both acute and chronic effects across multiple RCTs.
Findings: Consistent evidence across multiple RCTs that chronic Bacopa supplementation (300-450 mg standardized extract daily for 8-12 weeks) improves higher-order cognitive processes including learning, memory, and information processing. All studies required a minimum of 4-6 weeks before significant effects emerged. No reliable evidence of acute cognitive enhancement. Anxiolytic effects consistently observed alongside cognitive improvements. Bacopa was well-tolerated in all reviewed studies with primarily mild GI side effects.
Limitations: Small sample sizes in most studies (n=20-80). Short study durations. Lack of head-to-head comparisons with pharmaceutical cognitive enhancers or other nootropic herbs. Limited data on dose-response relationships. Most studies in healthy volunteers rather than clinical populations with cognitive impairment.
[6]
Chronic effects of Bacopa on cognitive function (Stough 2001)
Double-blind, placebo-controlled RCT evaluating the chronic cognitive and mood effects of Bacopa monnieri extract (CDRI 08, KeenMind) in 46 healthy adults aged 18-60 years over 90 days.
Findings: Bacopa (300 mg/day CDRI 08) significantly improved speed of visual information processing (Inspection Time task, P=0.008), learning rate (Rey Auditory Verbal Learning Test, P<0.05), and memory consolidation compared to placebo after 90 days. State Anxiety scores (STAI) were significantly reduced in the Bacopa group (P<0.05). No significant effects on short-term memory. No cognitive improvements were detected at the 5-week interim assessment, confirming the need for chronic administration.
Limitations: Small sample size (n=46). Single-center study. Only one dose level tested (300 mg). No evaluation of dose-response. Limited diversity in study population. Absence of biomarker measures to correlate with cognitive outcomes.
[7]
Chronic effects of Bacopa on cognitive function: follow-up study (Stough 2008)
Double-blind, placebo-controlled RCT examining the chronic cognitive effects of CDRI 08 Bacopa extract (300 mg/day for 90 days) in 62 healthy adults using an expanded neuropsychological battery.
Findings: Bacopa significantly improved performance on the Stroop task (P<0.05), indicating enhanced cognitive flexibility and executive function. Improved working memory performance was confirmed. The study replicated and extended the 2001 findings, demonstrating consistent cognitive benefits across multiple cognitive domains after 90 days of supplementation. Verbal learning and memory consolidation improvements were again observed.
Limitations: Moderate sample size (n=62). Single dose level. 90-day duration does not address long-term effects. Drop-out rate was notable. Healthy volunteers only; applicability to clinical cognitive impairment not established.
[8]
Bacopa and memory retention (Roodenrys 2002)
Double-blind, placebo-controlled RCT evaluating Bacopa monnieri (300 mg/day standardized extract for 12 weeks) on memory performance in 76 healthy adults aged 40-65 years.
Findings: Bacopa significantly improved the retention of new information (verbal learning — Rey Auditory Verbal Learning Test, delayed recall, P<0.05) compared to placebo. Speed of early information processing was also improved. The effect was specifically on the rate of forgetting: Bacopa-treated participants retained significantly more newly learned information over time compared to placebo. No significant effect on attention, short-term memory, or retrieval of pre-existing memories.
Limitations: Moderate sample size (n=76). Single-dose study. Effect was specific to retention of new information, not all cognitive domains. Did not include biomarker analysis. Middle-aged to older adults only.
[9]
Comprehensive review of Bacopa pharmacology and clinical evidence
Comprehensive narrative review covering the ethnopharmacology, phytochemistry, pharmacology, toxicology, and clinical trial evidence for Bacopa monnieri.
Findings: Bacopa demonstrates a multi-target pharmacological profile: (1) Antioxidant neuroprotection via free radical scavenging and upregulation of endogenous antioxidant enzymes; (2) Cholinergic modulation through enhancement of acetylcholine release and inhibition of acetylcholinesterase; (3) Serotonergic effects including increased 5-HT synthesis and modulation of 5-HT receptors; (4) Dopaminergic modulation; (5) GABAergic effects contributing to anxiolysis and anticonvulsant activity; (6) Anti-inflammatory and anti-amyloidogenic effects relevant to neurodegeneration. Animal studies demonstrate enhancement of dendritic branching and synaptic density in hippocampal neurons. Safety profile is favorable with primarily mild GI effects.
Limitations: As a narrative review, lacks formal meta-analytic synthesis. Animal-to-human translation of mechanisms is uncertain. Many preclinical findings await clinical confirmation.
[14]
KeenMind (CDRI 08) and Synapsa standardized extract research
Summary of research on the two most widely studied standardized Bacopa monnieri extracts: CDRI 08 (KeenMind, developed at the Central Drug Research Institute, India) and Synapsa (developed by PLT Health Solutions).
Findings: CDRI 08 (KeenMind): Standardized to contain not less than 55% combined bacosides. This is the most clinically studied Bacopa extract worldwide, with multiple RCTs supporting cognitive enhancement in adults and elderly populations (Stough 2001, 2008; Roodenrys 2002; Pase 2012). Typical dose: 300 mg/day. Synapsa: A standardized Bacopa extract (BSPE, Bacopa monnieri Special Extract) with demonstrated efficacy for working memory, visual processing, and multi-tasking in RCTs (Benson et al. 2014). Both extracts represent well-characterized, clinically validated forms that provide reproducible bacoside content. BacoMind: Another standardized extract developed in India containing specific ratios of 9 bioactive compounds. These standardized extracts are preferred over non-standardized Bacopa powders for clinical and commercial use due to consistent constituent profiles.
Limitations: Each standardized extract has its own clinical evidence base; findings are not automatically interchangeable between different extracts. Industry-funded research is common. Limited head-to-head comparisons between different Bacopa extract types.
Preparations & Dosage
Standardized Extract
Strength: Standardized to 20-55% total bacosides (calculated as bacoside A). CDRI 08: 55% bacosides. BacoMind: standardized to 9 specific bioactive compounds.
Commercially prepared standardized Bacopa monnieri extract capsules or tablets. Look for products standardized to total bacoside content (typically 20-55% bacosides). The most clinically studied extracts are CDRI 08 (KeenMind) standardized to 55% bacosides and Synapsa. Take with food to reduce GI side effects.
300-450 mg standardized extract daily (containing approximately 120-150 mg bacosides). The 300 mg dose of CDRI 08 (55% bacosides) is the most extensively studied. Some protocols use 450 mg/day. Take as a single dose or divided into two doses (morning and evening).
Once or twice daily with food
Minimum 8-12 weeks for cognitive effects to become apparent. Most clinical trials used 90-day (12-week) protocols. Long-term use (6-12 months or more) is consistent with the traditional Ayurvedic rasayana approach. No established upper limit for duration, but periodic reassessment is prudent.
Children 6-12 years: 100-225 mg standardized extract daily (studies in children have used various doses; consult practitioner). Bacopa has a long history of traditional use in children in India.
This is the preparation form with the strongest clinical evidence. Standardized extracts provide consistent bacoside dosing, which is critical for reproducible cognitive effects. Always take with food (a fat-containing meal is ideal) to enhance absorption of lipophilic bacosides and reduce the GI side effects (nausea, cramping) that are the most common complaint. The CDRI 08 extract at 300 mg/day is the gold-standard research dose. Non-standardized Bacopa powder products may contain highly variable bacoside levels.
capsule-powder
Strength: Crude dried herb powder containing approximately 2-5% total bacosides (variable depending on plant quality and processing)
Fill capsules with finely powdered dried Bacopa monnieri whole herb (aerial parts). This non-standardized form is less clinically studied than standardized extracts but is widely available and used in traditional practice.
500-1500 mg dried herb powder, 2-3 times daily (total daily dose 1000-3000 mg). Higher doses are needed compared to standardized extracts because the bacoside content of raw herb powder is lower (typically 2-5% bacosides).
2-3 times daily with meals
Minimum 8-12 weeks. Consistent with long-term traditional use.
Children over 6: 250-500 mg, 1-2 times daily. Consult practitioner.
Less clinically studied than standardized extracts. Bacoside content is highly variable depending on plant source, growing conditions, harvest timing, and processing methods. The higher doses required increase the likelihood of GI side effects. For consistent therapeutic results, standardized extracts are preferred. However, crude herb powder may contain synergistic co-constituents not present in concentrated extracts.
[6]
Infusion (Tea)
Strength: 2-4 g dried herb per 240 mL water
Steep 2-4 g of dried Bacopa monnieri herb in 240 mL (8 oz) of just-boiled water for 10-15 minutes, covered. Strain and drink. The infusion has a markedly bitter taste; honey may be added for palatability.
1 cup (240 mL), 2-3 times daily
2-3 times daily
Long-term use consistent with traditional practice
Children over 6: half adult dose, with honey for palatability. Consult practitioner.
Traditional preparation in Ayurvedic practice, though the fresh juice (swarasa) is the classical preparation described in ancient texts. The infusion extracts water-soluble constituents including some saponins and flavonoids, though extraction efficiency for the full range of bacosides may be lower than alcohol-based preparations. The bitter taste is characteristic and considered therapeutically relevant as a digestive bitter. Adding milk or ghee (traditional anupana) may enhance absorption of lipophilic bacosides.
[14]
Tincture
Strength: Dried herb: 1:5, 45-60% ethanol. Fresh herb: 1:2, 60-70% ethanol.
Macerate dried Bacopa monnieri herb in 45-60% ethanol at a ratio of 1:5 for 2-4 weeks. Shake daily. Press and filter. For fresh plant tincture: use 1:2 ratio in 60-70% ethanol.
2-4 mL (approximately 40-80 drops), 3 times daily
3 times daily
Long-term use as nervine tonic
Not recommended for children due to alcohol content. Use glycerite instead (see below).
Alcohol-based extraction effectively captures both water-soluble and lipid-soluble constituents including bacosides. A moderate alcohol percentage (45-60%) provides good extraction of the triterpenoid saponins. Can be added to formulas with other nervine and nootropic herbs (e.g., gotu kola, rosemary, lemon balm). Some practitioners prefer a slightly higher alcohol percentage for optimal saponin extraction.
[14]
ghee-preparation
Strength: Classical ratio: 1 part herb : 4 parts ghee : 16 parts water (cooked until water evaporates)
Traditional Ayurvedic preparation: Cook Bacopa herb (fresh or dried) in ghee (clarified butter) at low heat for an extended period. Classical method: Combine 1 part Bacopa herb with 4 parts ghee and 16 parts water, then cook slowly until all water evaporates and only the medicated ghee remains. Known as 'Brahmi Ghrita' (Brahmi ghee).
1-2 teaspoons (5-10 mL) of medicated ghee, 1-2 times daily, typically on an empty stomach or with warm milk
1-2 times daily
Long-term rasayana use (traditionally described as cycles of weeks to months)
Children over 2: 1/4-1/2 teaspoon daily. Traditional use in children is well-established in Ayurveda.
Brahmi Ghrita is one of the most revered traditional preparations in Ayurveda for cognitive enhancement and nervous system rejuvenation. The ghee serves multiple purposes: (1) it is a lipid vehicle that enhances absorption of lipophilic bacosides; (2) ghee is considered a yogavahi (catalytic carrier) that enhances the potency and tissue penetration of herbs in Ayurvedic pharmacology; (3) it masks the bitter taste, making the preparation palatable. This preparation is specifically described in the Charaka Samhita as a medhya rasayana. Modern understanding of bacoside lipophilicity supports the traditional rationale for ghee as a vehicle.
Fresh Juice / Expressed Juice
Strength: Undiluted fresh pressed juice of whole plant
Crush fresh Bacopa monnieri whole plant and extract the juice by pressing through cheesecloth or using a juicer. The fresh juice (swarasa) is the classical Ayurvedic preparation described in the Charaka Samhita.
10-20 mL fresh juice, 1-2 times daily, mixed with honey, ghee, or warm milk as an anupana (vehicle)
1-2 times daily, typically morning
Seasonal use (traditionally during specific seasons/ritus) or long-term rasayana
Children over 2: 5-10 mL fresh juice with honey (not for infants under 1 year due to honey). Traditional use in children is well-established.
The most classical Ayurvedic preparation of Brahmi as described in the Charaka Samhita (Chikitsasthana). Fresh juice (swarasa) is considered the most potent form in traditional Ayurvedic pharmacology. Requires access to fresh plant material, making it impractical for most commercial applications. The juice is intensely bitter. Mixing with ghee (Brahmi Ghrita preparation) or honey is both traditional and practical. This form has not been used in modern clinical trials, which have used dried extracts instead.
[14]
Syrup
Strength: Concentrated Bacopa decoction with 1:1 sugar or honey
Prepare a strong decoction of dried Bacopa herb (30-50 g per 500 mL water, simmered 20-30 minutes). Strain and add equal weight of sugar or honey. Simmer gently until syrupy consistency. Store refrigerated.
1-2 teaspoons (5-10 mL), 2 times daily
1-2 times daily
As needed; suitable for long-term use
Children over 2: 1/2-1 teaspoon daily. Do not give honey-based syrups to infants under 1 year (botulism risk).
Palatable form particularly useful for children, who are a traditional target population for Bacopa supplementation. The sweet vehicle partially masks the intense bitter taste. Sugar acts as a preservative (refrigerated shelf life approximately 2-3 weeks). Commercial Brahmi syrups are widely available in India and marketed for children's cognitive development and academic performance.
[14]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Allergic reactions to Bacopa are rare but theoretically possible. No well-documented cases of serious allergic reactions (anaphylaxis) have been reported in the literature. Discontinue use if any signs of allergic reaction occur.
There are no controlled studies of Bacopa monnieri in pregnant or lactating women. While Bacopa has a long history of traditional use in India (including in children), formal reproductive toxicity data in humans is insufficient to establish safety during pregnancy and lactation. Animal reproductive toxicity studies have not shown teratogenicity at standard doses, but data is limited. Avoid use during pregnancy and lactation as a precaution until more safety data is available.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Thyroid medications (levothyroxine, liothyronine) (Thyroid hormones) | theoretical | Animal studies suggest Bacopa may stimulate thyroid function and increase T4 (thyroxine) levels. The mechanism may involve stimulation of thyroid peroxidase activity or increased iodine uptake by the thyroid gland. In hyperthyroid patients or those on exogenous thyroid hormone, this could lead to excess thyroid activity. |
| Anticholinergic drugs (atropine, scopolamine, diphenhydramine, oxybutynin, TCAs) (Anticholinergics) | theoretical | Bacopa enhances cholinergic neurotransmission and may increase acetylcholine levels. This is pharmacologically antagonistic to anticholinergic drugs, potentially reducing their efficacy. |
| CNS depressants (benzodiazepines, barbiturates, zolpidem, gabapentin) (Sedatives and anxiolytics) | theoretical | Bacopa has demonstrated anxiolytic effects mediated through GABAergic modulation. Additive sedation is theoretically possible when combined with other CNS depressants. |
| Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) (Cholinesterase inhibitors) | theoretical | Bacopa modulates cholinergic transmission and may have mild acetylcholinesterase inhibitory activity. Combination with pharmaceutical AChE inhibitors could theoretically lead to excessive cholinergic stimulation. |
| Antihypertensive agents (calcium channel blockers, beta-blockers) (Antihypertensive agents) | theoretical | Bacopa has demonstrated mild vasodilatory and potential hypotensive effects in animal studies. Additive blood pressure reduction is theoretically possible. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
Pregnancy: No controlled human studies during pregnancy. Animal reproductive toxicity studies have not demonstrated teratogenicity at standard therapeutic doses; however, comprehensive reproductive toxicity data (including effects on fertility, embryo-fetal development, and peri/postnatal development) is limited. Despite a long history of traditional use in India (including in children and young women), the absence of formal safety data in pregnancy warrants a precautionary approach. Avoid during pregnancy unless benefits clearly outweigh potential risks and under medical supervision. Lactation: No data on excretion of bacosides or other Bacopa constituents into breast milk. Traditional use in lactating women in India exists but is not well-documented in modern literature. Avoid during lactation until safety data is available. NOTE: The traditional Ayurvedic use of Bacopa in children (from very young ages) provides some indirect reassurance about low acute toxicity, but this does not substitute for formal pregnancy/lactation safety data.
Adverse Effects
References
Monograph Sources
- [1] National Center for Complementary and Integrative Health (NCCIH). Bacopa. NCCIH, National Institutes of Health (2024)
- [2] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Herba Bacopae Monnierae (draft assessment). World Health Organization, Geneva (2009)
- [3] Indian Pharmacopoeia Commission. Bacopa monnieri (Brahmi) monograph. Ayurvedic Pharmacopoeia of India, Part I, Volume I (2001)
- [4] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. Assessment report on Bacopa monnieri (L.) Wettst., herba (Community herbal monograph review). European Medicines Agency (2014)
Clinical Studies
- [5] Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Scholfield CN. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol (2014) ; 151 : 528-535 . DOI: 10.1016/j.jep.2013.11.008 . PMID: 24252493
- [6] Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med (2008) ; 14 : 707-713 . DOI: 10.1089/acm.2008.0018 . PMID: 18611150
- [7] Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) (2001) ; 156 : 481-484 . DOI: 10.1007/s002130100815 . PMID: 11498727
- [8] Stough C, Downey LA, Lloyd J, Silber B, Rothenberg S, Hutchison CW, Nathan PJ. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res (2008) ; 22 : 1629-1634 . DOI: 10.1002/ptr.2537 . PMID: 18683852
- [9] Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology (2002) ; 27 : 279-281 . DOI: 10.1016/S0893-133X(01)00419-5 . PMID: 12093601
- [10] Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med (2012) ; 18 : 647-652 . DOI: 10.1089/acm.2011.0367 . PMID: 22747190
- [11] Raghav S, Singh H, Dalal PK, Srivastava JS, Asthana OP. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J Psychiatry (2006) ; 48 : 238-242 . DOI: 10.4103/0019-5545.31555 . PMID: 20703343
Traditional Texts
- [12] Charaka (attributed); translated by Sharma PV. Charaka Samhita: Text with English Translation and Critical Exposition (Chikitsasthana, Chapter 1 — Rasayana). Chaukhambha Orientalia, Varanasi (2001)
- [13] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone/Elsevier (2013)
Pharmacopeias & Reviews
- [14] Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res (2013) ; 16 : 313-326 . DOI: 10.1089/rej.2013.1431 . PMID: 23772955
- [15] Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Indian J Pharmacol (1997) ; 29 : S359-S365
Last updated: 2026-02-26 | Status: review